Multiplate® analyzer

Mulitplate Analyzer

Multiplate analyzer


A reliable tool for testing platelet function1

The Multiplate® system may be used to personalize anti-platelet therapy and/or to stratify bleeding risk and – with small volumes of whole blood.

Blood platelets play a pivotal role in physiological hemostasis. Disorders of platelet function in general manifest most clearly as either as bleedings or thrombotic disorders hence platelet function testing can be utilized in the analysis of inherited and acquired platelet function disorders. The Multiplate® Analyzer can detect platelet dysfunction and thus may be used to aid in the diagnosis and clinical management of patients with platelet function disorders2,3.

The Multiplate® Analyzer may also be used to monitor the patient’s response to antiplatelet drugs and guide selection of antiplatelet therapies4. The Multiplate® Analyzer was the device used in the first large randomised controlled trial that demonstrated the safety and efficacy of switching of drug regimen based on platelet function testing (PFT), TROPICAL ACS5. In the TROPICAL-ACS study, patients with acute coronary syndrome undergoing PCI were treated with either 1) one week of prasugrel followed by 1 week of clopidogrel and PFT-guided maintenance therapy with clopidogrel or prasugrel or 2) with prasugrel only. There were no differences in ischaemic and bleeding events in both groups with this approach. The authors conclude: “Guided de-escalation of antiplatelet treatment was non-inferior to standard treatment with prasugrel at 1 year after PCI in terms of net clinical benefit”. Hence early de-escalation of antiplatelet treatment from prasugrel to clopidogrel guided by Multiplate® platelet function testing results could be an alternative approach to standard treatment regimens5.

The Multiplate® Analyzer may also be used as a pre-surgical and/or perioperative tool to aid in the prediction of bleeding and for monitoring the efficacy of various types of prohemostatic therapies(6-9). Studies have shown that Multiplate® results, used in conjunction with clinical presentation and additional laboratory markers, may be used to help determine timing of surgery after stopping antiplatelet therapy10, 11. Multiplate® results may also be used to assess platelet function perioperative and could be integrated into institution transfusion algorithm to reduce platelet transfusion rates and hence risks from potential complications of platelet transfusion12. Reduced platelet transfusions may also help to reduce costs. 


  • High throughput: 30 tests/hour
  • Whole blood sample anticoagulated with hirudin eliminates need for sample preparation, reduces risk of pre-analytical errors
  • Low sample volume: only 300 μL whole blood per analysis
  • Fast turn-around time: 10 min./test
  • Easy to use: only 3 pipetting steps

Test principle

  • Multiplate® analyzer provides a disposable test cuvette featuring a duplicate sensor
  • Patented twin sensor technology (Multiple Electrode Aggregometry (MEA) for reliable results and quality control
  • Whole blood testing eliminates the need for time-consuming sample preparation while maintaining the natural physiological matrix for platelet function
  • Small quantity (300µL) of whole blood required per test
  • Upon activation platelets aggregate on metal sensors and increase the electrical resistance

Multiplate test principle

Helping to guide cost-effective therapeutic approaches

  • in coronary interventions5,13,14
  • in cardiac surgeries10, 15
  • in vascular surgeries9, 15
  • in peripheral vascular interventional procedures17 
  • prevention of stent occlusion/reocclusion16

Fast and easy assessment

  • of platelet function from small volumes of whole blood


  • for tailored anti-platelet regimen
  • for stratification of bleeding risk in surgical and interventional procedures
  • aid in diagnosis of inherited PF disorders

Medical momentum

  • More than 600 Medline publications 2006 and consensus papers with Multiplate and published guidelines for PFT
  • More than 10 years’ study experience

Consistent results

  • Standardized reagents and procedures
  • Computer-based system, operates with automatic pipette and system performance controls

Comprehensive menu of CE-marked reagents

ADPtest Assay for the quantitative in vitro determination of platelet function following stimulation of the platelet adenosine diphosphate (ADP) receptors. The ADPtest assay may be used to detect an inhibition of the P2Y12 receptor, as well as an inhibition or absence of the GpIIb/IIIa receptor
ASPItest Assay for the quantitative in vitro determination of platelet function triggered by arachidonic acid.  The ASPItest may be used to detect an inhibition of the platelet cyclooxygenase, as well as an inhibition or absence of the GpIIb/IIIa receptor
TRAPtest Assay for the quantitative in vitro determination of platelet function triggered by TRAP-6. Thrombin receptor activating peptide-6 (TRAP-6) is a potent platelet activator and stimulates platelet aggregation via the thrombin receptor PAR-1.  The TRAPtest may be used to detect platelet function triggered via the thrombin receptor without triggering fibrin formation
COLtest Assay for the quantitative in vitro determination of platelet function triggered by collagen 
RISTOtest Assay for the quantitative in vitro determination of von Willebrand Factor (vWF)- and glycoprotein Ib (GpIb)-dependent platelet aggregation with whole blood samples on the Multiplate® analyzer
ASA reagent Inhibitor of cyclooxgenase.  Addition of ASA reagent to the blood sample leads to reduced aggregation responses in the ASPItest and the COLtest
GpIIbIIIa antagonist reagent Inhibitor of the platelet GpIIbIIIa receptor.  Addition of the GpIIbIIIa reagent to the blood sample leads to strongly reduced aggregation in the TRAPtest
Liquid Control Set Quality control for electrical signal in impedance aggregometry based on the analysis of an artificial liquid control material

1. Karon, BS. et. al. (2014), Clinical Chemistry, 60:1524-1531
2. Gresele, P. et al. (2015), Haemost., 13:314-322
3. Harrison, P. et. al. (2013), Hematol Oncol Clin N Am, 27:411-441
4. Aradi, D. et. al. (2015), Throm Haemost, 113:221-230
5. Sibbing, D. et. al. (2017), Lancet, Aug 27 [e-pub]
6. Ranucci, M. et al. (2011), Ann Thorac Surg, 91(1):123-9
7. Weber, C.F. et al. (2012), Anesthesiology, Sep, 117(3):531-47
8.Rafiq, S. et al. (2016), J Card Surg, 31(9):565-71
9. Ferraris, VA. etl al. (2012), Ann Thorac Surg, 94:1761-1781
10. Kong, R. et al. (2014), Int Jnl Lab Hem, 37:143-147
11. Straub, N. et al. (2013). Thromb Haemost, 111(2):290-299
12. Pape, A. et. al (2010), ISBT Science Series, 5:161-168
13.Aradi, D. et. al. (2014), Euro Heart J, 35:209-215
14. Aradi, D. et. al. (2013), Int J Cardiol, 167:2140-2148
15. Ranucci, M. et. al. (2017), Interact Cardiovasc Thorac Surg, 24:196-202
16. Byrne, R.A. et al. (2015), Euro Heart J, 36:3320-3331
17. Rajagopalan, S. et. al. (2007), J Vasc Surg, 46:485-490